Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03674294
Other study ID # Aprepitant-CINV
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date August 4, 2015
Est. completion date June 1, 2020

Study information

Verified date February 2023
Source Sun Yat-sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to study whether adding Aprepitant to Palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI or FOLFOX chemotherapy regimen among gastrointestinal malignancy patients with high risk factors of chemotherapy-associated adverse events.


Description:

The purpose of this study is to study whether adding Aprepitant to Palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI or FOLFOX chemotherapy regimen after curative effect among gastrointestinal malignancy patients with high risk factors of chemotherapy-associated adverse events.This study will observe and evaluate the incidence and severity of nausea and vomiting as well as the effectiveness of corresponding treatment(with or without Aprepitant) during Day 1 to Day 5 from the beginning of chemotherapy.


Recruitment information / eligibility

Status Completed
Enrollment 248
Est. completion date June 1, 2020
Est. primary completion date March 31, 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Diagnosed by pathology as gastrointestinal carcinoma and no previous FOLFOX or FOLFIRI based regimen chemotherapy history. - Female. - Adult patients ( = 18, = 50 years of age) - No long-term or excessive alcohol intake history:1.Alcohol intake less than 5 times per week; 2.Alcohol intake less than 100g per day. - Performance status ECOG 0-1 - Adequate haematological, hepatic, renal and metabolic function parameters: Leukocytes : 3,500-10,000/mm3, ANC = 1,500/mm3, Platelets = 90,000/mm3, Hb > 9g/dl (may be transfused or treated with erythropoietin to maintain or exceed this level), Serum creatinine = 1 x upper limit of normal, Bilirubin = 1.5 x upper limit of normal, Serum AST, ALT, ALP = 2.5 x upper limit of normal in absence of liver metastases, or = 5 x upper limit of normal in presence of liver metastases. - Negative pregnancy test. If pregnancy test were positive, subject should be included in the trial only when the subsequent pregnancy test is negative. - Ability of reading, comprehending and finishing trial questionnaires and record, including VAS (Visual Analogue Scale) question. - Before subject registration, written informed consent must be given according to local regulations. Exclusion Criteria: - Pregnant women without morning sickness. - Presence of gastrointestinal tract obstruction or electrolyte imbalance. - Any history of central nervous system disease(e.g. Primary brain tumour, seizure not controlled with standard medical therapy, brain metastases or history of stroke). - Contraindication of glucocorticoid:1.Infection of virus, bacteria or fungus uncontrolled by antibiotics; 2.Active stomach or duodenum ulcer; 3.Severe hypertension, atherosclerosis, diabetes; 4.Osteoporosis;5.Corneal ulcer; 6.Pregnancy; 7.Reparative phase of trauma, operation or fraction; 8.Hypercortisolism; 9.Severe mental disorder or epilepsy; 10.Inadequate cardiac or renal function. - Mental disability or severe emotional or mental disorder. - Active infection(e.g. pneumonia, hepatitis) or any uncontrolled disease(e.g.diabetic ketoacidosis) that may affect study outcome or expose patients to unnecessary risk. - Usage of any illicit drug, including medical marijuana or alcohol abusing(China drug dependence criteria). - Treatment of unapproved medicine in the previous 4 weeks. - Concomitant therapy of psychotropic medicine such as olanzapine. - Hypersensitivity history towards Aprepitant, 5-HT3 receptor antagonist or dexamethasone. - Previous treatment of Aprepitant. - Unable to swallow capsules. - Main researchers considered that the patient is unsuited to the trial. - Unable or unwilling to follow research programme.

Study Design


Intervention

Drug:
Aprepitant
Aprepitant is manufactured by Merck & Co. for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. It was approved by the FDA in 2003
Palonosetron
Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV-nausea and vomiting and there are tentative data to suggest that it may be more effective than granisetron.
Dexamethasone
Dexamethasone is a type of corticosteroid medication. It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis.
Placebo Oral Tablet
In the current clinical trial, placebo oral tablet is provided as a substance for Aprepitant with no active therapeutic effect.

Locations

Country Name City State
China Sun Yat-sen University Cancer Center Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complete response rate during the overall phase The proportion of patients without emesis episodes or rescue medication use during the overall phase (0-120 h) Up to 1-2 months
Secondary Complete response rate in the acute phase The proportion of patients without emesis episodes or rescue medication use during the acute phase (0-24h) Up to 1-2 months
Secondary Complete response rate in the delayed phase The proportion of patients without emesis episodes or rescue medication use during the delayed phase (25-120 h) Up to 1-2 months
Secondary No vomiting rate in the acute phase, delayed phase and overall phase The proportion of no vomiting (no vomiting or retching episodes) in the acute phase, delayed phase and overall phase Up to 1-2 months
Secondary Affection caused by CINV reported by patients Up to 1-2 months
Secondary Effects of CINV on daily life Up to 1-2 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Completed NCT05178095 - Artificial Intelligence in Colonic Polyp Detection N/A
Recruiting NCT03602677 - Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage N/A
Not yet recruiting NCT05552729 - Effects of Different Doses of Vitamin D on Cancer-related Cognitive Impairment in Patients With Gastrointestinal Tumors Phase 1/Phase 2
Recruiting NCT02871245 - Clinical Trial on Acupuncture Therapy in Patients With Gastrointestinal Neoplasms Laparoscopic Surgery N/A
Completed NCT04694521 - Outcomes of Side-to-end Versus End-to-end Colorectal Anastomosis in Non-emergent Sigmoid and Rectal Cancers: Randomized Controlled Clinical Trial N/A
Not yet recruiting NCT02860429 - Clinical Trial of Cinobufacini Injection Combined With Oxaliplatin Regimen on Gastrointestine Carcinoma Phase 4
Completed NCT02454647 - Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients N/A
Recruiting NCT02196935 - Los Angeles Prospective GI Biliary and EUS Series
Completed NCT00190801 - Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced Gastric Carcinoma Phase 2
Completed NCT00289445 - Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment) Phase 1/Phase 2
Completed NCT04010227 - Telephone Support for Advanced Gastrointestinal Cancer Patients and Caregivers N/A
Recruiting NCT03330964 - Clinical Trial of Electroacupuncture Stimulation on Prevention and Treatment of Oxaliplatin Neurotoxicity N/A
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Recruiting NCT05322486 - Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
Completed NCT03549494 - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Phase 2
Completed NCT03559543 - Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Phase 2
Recruiting NCT02672774 - Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal Cancers N/A
Completed NCT02444572 - Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox® Phase 4